EP3179393A3 - Gene expression profile algorithm and test for determining prognosis of prostate cancer - Google Patents

Gene expression profile algorithm and test for determining prognosis of prostate cancer Download PDF

Info

Publication number
EP3179393A3
EP3179393A3 EP16191856.0A EP16191856A EP3179393A3 EP 3179393 A3 EP3179393 A3 EP 3179393A3 EP 16191856 A EP16191856 A EP 16191856A EP 3179393 A3 EP3179393 A3 EP 3179393A3
Authority
EP
European Patent Office
Prior art keywords
prostate cancer
test
gene expression
expression profile
determining prognosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP16191856.0A
Other languages
German (de)
French (fr)
Other versions
EP3179393A2 (en
EP3179393B1 (en
Inventor
Steve Shak
Mark Lee
William Novotny
Tara Maddala
Michael Crager
Diana Cherbavaz
Robert PELHAM
Carl L. Millward
Dejan Knezevic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genomic Health Inc
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Priority to EP20180564.5A priority Critical patent/EP3739595A3/en
Publication of EP3179393A2 publication Critical patent/EP3179393A2/en
Publication of EP3179393A3 publication Critical patent/EP3179393A3/en
Application granted granted Critical
Publication of EP3179393B1 publication Critical patent/EP3179393B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Data Mining & Analysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.
EP16191856.0A 2012-01-31 2013-01-28 Gene expression profile algorithm and test for determining prognosis of prostate cancer Active EP3179393B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP20180564.5A EP3739595A3 (en) 2012-01-31 2013-01-28 Gene expression profile algorithm and test for determining prognosis of prostate cancer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261593106P 2012-01-31 2012-01-31
US201261672679P 2012-07-17 2012-07-17
US201261713734P 2012-10-15 2012-10-15
PCT/US2013/023409 WO2013116144A1 (en) 2012-01-31 2013-01-28 Gene expression profile algorithm and test for determining prognosis of prostate cancer
EP13743785.1A EP2809812A4 (en) 2012-01-31 2013-01-28 Gene expression profile algorithm and test for determining prognosis of prostate cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP13743785.1A Division EP2809812A4 (en) 2012-01-31 2013-01-28 Gene expression profile algorithm and test for determining prognosis of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP20180564.5A Division EP3739595A3 (en) 2012-01-31 2013-01-28 Gene expression profile algorithm and test for determining prognosis of prostate cancer

Publications (3)

Publication Number Publication Date
EP3179393A2 EP3179393A2 (en) 2017-06-14
EP3179393A3 true EP3179393A3 (en) 2017-09-13
EP3179393B1 EP3179393B1 (en) 2020-07-08

Family

ID=48870540

Family Applications (3)

Application Number Title Priority Date Filing Date
EP20180564.5A Withdrawn EP3739595A3 (en) 2012-01-31 2013-01-28 Gene expression profile algorithm and test for determining prognosis of prostate cancer
EP16191856.0A Active EP3179393B1 (en) 2012-01-31 2013-01-28 Gene expression profile algorithm and test for determining prognosis of prostate cancer
EP13743785.1A Withdrawn EP2809812A4 (en) 2012-01-31 2013-01-28 Gene expression profile algorithm and test for determining prognosis of prostate cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP20180564.5A Withdrawn EP3739595A3 (en) 2012-01-31 2013-01-28 Gene expression profile algorithm and test for determining prognosis of prostate cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP13743785.1A Withdrawn EP2809812A4 (en) 2012-01-31 2013-01-28 Gene expression profile algorithm and test for determining prognosis of prostate cancer

Country Status (14)

Country Link
US (3) US8725426B2 (en)
EP (3) EP3739595A3 (en)
JP (3) JP6351112B2 (en)
AU (3) AU2013215448B2 (en)
CA (1) CA2863040C (en)
CO (1) CO7051010A2 (en)
DK (1) DK3179393T3 (en)
ES (1) ES2812105T3 (en)
HK (1) HK1201881A1 (en)
IL (3) IL233709A (en)
MX (3) MX366164B (en)
NZ (2) NZ722902A (en)
SG (3) SG10201912312YA (en)
WO (1) WO2013116144A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX366164B (en) * 2012-01-31 2019-07-01 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer.
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
WO2015094854A1 (en) * 2013-12-18 2015-06-25 Pacific Biosciences Inc. Iterative clustering of sequence reads for error correction
CN103695560B (en) * 2014-01-09 2016-09-14 上海交通大学医学院附属瑞金医院 The application in colorectal carcinoma chemotherapy Outcome measure and detection kit of the PPP1R12A gene
US10364469B2 (en) * 2014-01-16 2019-07-30 Illumina, Inc Gene expression panel for prognosis of prostate cancer recurrence
WO2015131177A1 (en) * 2014-02-28 2015-09-03 The Johns Hopkins University Genes encoding secreted proteins which identify clinically significant prostate cancer
ES2838923T3 (en) 2014-10-24 2021-07-02 Koninklijke Philips Nv Medical prognosis and prediction of response to treatment using multiple activities of the cell signaling pathway
CN108064311B (en) 2014-10-24 2022-10-28 皇家飞利浦有限公司 Medical prognosis and prediction of treatment response using multiple cell signaling pathway activities
WO2016062891A1 (en) 2014-10-24 2016-04-28 Koninklijke Philips N.V. ASSESSMENT OF TGF-β CELLULAR SIGNALING PATHWAY ACTIVITY USING MATHEMATICAL MODELLING OF TARGET GENE EXPRESSION
CN104880565A (en) * 2015-05-04 2015-09-02 贵州省人民医院 Detection reagent for prognosis of ZFP36 prostatic cancer and kit of detection reagent
WO2016193110A1 (en) * 2015-05-29 2016-12-08 Koninklijke Philips N.V. Methods of prostate cancer prognosis
ES2754434T3 (en) * 2015-05-29 2020-04-17 Koninklijke Philips Nv Prostate Cancer Prognosis Methods
EP3318632B8 (en) * 2015-07-01 2022-12-14 Fujita Academy Marker for heterogeneity of cancer tissue, and use thereof
DK3334837T3 (en) 2015-08-14 2021-02-15 Koninklijke Philips Nv EVALUATION OF NFKB CELLULAR SIGNALING VEHICLE ACTIVITY USING MATHEMATICAL MODELING OF MOAL EXPRESSION
WO2017062505A1 (en) * 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
CA3011106A1 (en) * 2016-01-20 2017-07-27 Dana-Farber Cancer Institute, Inc. Compositions and methods for screening and identifying clinically aggressive prostate cancer
ES2688213T3 (en) * 2016-07-15 2018-10-31 Proteomedix Ag Method to detect proteins in human samples and uses of such methods
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US11586674B2 (en) * 2016-12-28 2023-02-21 Khalifa University of Science and Technology Methods and systems for searching
SG11201906318WA (en) * 2017-02-13 2019-08-27 Genomic Health Inc Algorithms and methods for assessing late clinical endpoints in prostate cancer
EP3593140A4 (en) * 2017-03-09 2021-01-06 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
US20200294617A1 (en) * 2017-10-27 2020-09-17 King Abdullah University Of Science And Technology A graph-based constant-column biclustering device and method for mining growth phenotype data
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502280A1 (en) * 2017-12-21 2019-06-26 Koninklijke Philips N.V. Pre-surgical risk stratification based on pde4d7 expression and pre-surgical clinical variables
US20210040563A1 (en) * 2018-01-25 2021-02-11 Sorbonne Universite Molecular signature and use thereof for the identification of indolent prostate cancer
MX2020008702A (en) * 2018-02-22 2020-09-25 Liquid Biopsy Res Llc Methods for prostate cancer detection and treatment.
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
CN109001467A (en) * 2018-07-20 2018-12-14 贵州省人民医院 A kind of gene association prognosis detection reagent and preparation method thereof for prostate cancer
GB201816820D0 (en) * 2018-10-16 2018-11-28 Univ York Diagnostic method
WO2020092808A1 (en) 2018-10-31 2020-05-07 Regents Of The University Of Minnesota Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer
CA3148611A1 (en) 2019-08-12 2021-02-18 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
EP3901288A1 (en) * 2020-04-20 2021-10-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multi-gene expression assay for prostate carcinoma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053223A2 (en) * 2001-12-21 2003-07-03 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
US20110153534A1 (en) * 2006-03-31 2011-06-23 Illumina, Inc. Expression Profiles to Predict Relapse of Prostate Cancer

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064627A2 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
JP2003528564A (en) 1998-06-06 2003-09-30 ジェノスティック ファーマ リミテッド Probes used for genetic profiling
WO2000040749A2 (en) 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
FI990382A0 (en) 1999-02-23 1999-02-23 Arctic Partners Oy Ab New diagnostic method
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
NZ520095A (en) 2000-01-13 2004-05-28 Genentech Inc Novel Stra6 polypeptides, nucleic acids, antibodies, compositions and methods of treatments for inhibiting tumor cell growth
AU2002214576A1 (en) 2000-10-13 2002-04-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genes related to development of refractory prostate cancer
WO2002074156A2 (en) 2001-02-02 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
CA2442820A1 (en) 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US20100297657A1 (en) 2001-08-02 2010-11-25 The Regents Of The University Of Michigan Expression profile of prostate cancer
KR20040064275A (en) 2001-11-09 2004-07-16 소스 프리시전 메디슨, 인코포레이티드 Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
WO2003050243A2 (en) 2001-12-10 2003-06-19 Millennium Pharmaceuticals Inc. Novel genes encoding colon cancer antigens
EP1483381A2 (en) 2002-03-14 2004-12-08 Exonhit Therapeutics S.A. Variants of human kallikrein-2 and kallikrein-3 and uses thereof
AUPS187002A0 (en) 2002-04-22 2002-05-30 Queensland University Of Technology Condition-specific molecules and uses therefor
WO2004025258A2 (en) 2002-09-10 2004-03-25 Sydney Kimmel Cancer Center Gene segregation and biological sample classification methods
WO2004108896A2 (en) 2003-06-03 2004-12-16 The Board Of Trustees Of The University Of Arkansas Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
US7526387B2 (en) 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
JP2005211023A (en) 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc Method for estimating possibility of metastasis or relapse of renal cell carcinoma
WO2005076005A2 (en) 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
US20070224596A1 (en) 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
DK2163650T3 (en) 2004-04-09 2015-11-02 Genomic Health Inc Genekspressionsmarkører for prediction of response to chemotherapy
CA2992180C (en) 2004-05-07 2021-02-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
WO2005117943A2 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Biomarkers for monitoring inhibition of impdh pathway
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
EP1784511A4 (en) 2004-08-13 2009-03-11 Millennium Pharm Inc Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US7666595B2 (en) 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
JP2008536488A (en) 2005-03-16 2008-09-11 シドニー キンメル キャンサー センター Methods and compositions for predicting cancer death and prostate cancer survival using gene expression signatures
US20090186024A1 (en) 2005-05-13 2009-07-23 Nevins Joseph R Gene Expression Signatures for Oncogenic Pathway Deregulation
US8278038B2 (en) 2005-06-08 2012-10-02 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1929306A4 (en) 2005-09-01 2009-11-11 Precision Therapeutics Inc Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
AU2006291054B2 (en) 2005-09-12 2011-10-13 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
CN101365806B (en) 2005-12-01 2016-11-16 医学预后研究所 For identifying method and apparatus and the purposes of prediction curative effect thereof of the biomarker of therapeutic response
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007070621A2 (en) 2005-12-13 2007-06-21 Children's Medical Center Corporation Prognosis indicators for solid human tumors
DK1974058T3 (en) 2006-01-11 2014-09-01 Genomic Health Inc Gene Expression Markers for Prognostication of Colorectal Cancer
ES2300176B1 (en) 2006-02-15 2009-05-01 Consejo Superior Investig. Cientificas METHOD FOR THE MOLECULAR PROSTATE CANCER DIAGNOSIS, KIT TO IMPLEMENT THE METHOD.
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
US7805183B2 (en) 2006-06-22 2010-09-28 Wisconsin Alumni Research Foundation Stromal collagen in the diagnosis and characterization of breast cancer
WO2008067065A2 (en) 2006-10-19 2008-06-05 Shiv Srivastava Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
JP2010509598A (en) * 2006-11-13 2010-03-25 ライフ テクノロジーズ コーポレーション Methods and kits for detecting prostate cancer biomarkers
EP2140020A2 (en) 2007-03-15 2010-01-06 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2008133877A1 (en) * 2007-04-23 2008-11-06 California Institute Of Technology Inhibitors for steroid response elements and related methods
US20090123439A1 (en) 2007-11-09 2009-05-14 The Jackson Laboratory Diagnostic and prognosis methods for cancer stem cells
WO2009114836A1 (en) 2008-03-14 2009-09-17 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US20090298082A1 (en) 2008-05-30 2009-12-03 Klee George G Biomarker panels for predicting prostate cancer outcomes
NZ590851A (en) 2008-07-16 2012-08-31 Dana Farber Cancer Inst Inc Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
US20110230361A1 (en) 2008-11-14 2011-09-22 Emory University Prostate cancer biomarkers to predict recurrence and metastatic potential
CN102308212A (en) 2008-12-04 2012-01-04 加利福尼亚大学董事会 Materials and methods for determining diagnosis and prognosis of prostate cancer
ES2595410T3 (en) 2009-01-07 2016-12-29 Myriad Genetics, Inc. Cancer biomarkers
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
US20100303795A1 (en) 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
ES2763899T3 (en) 2009-07-08 2020-06-01 Worldwide Innovative Network Method for predicting drug efficacy in a patient
MX337650B (en) 2009-11-23 2016-03-14 Genomic Health Inc Methods to predict clinical outcome of cancer.
CA3128103A1 (en) 2010-01-11 2011-07-14 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
SG186940A1 (en) * 2010-07-27 2013-02-28 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
MX366164B (en) * 2012-01-31 2019-07-01 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053223A2 (en) * 2001-12-21 2003-07-03 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
US20110153534A1 (en) * 2006-03-31 2011-06-23 Illumina, Inc. Expression Profiles to Predict Relapse of Prostate Cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LISA MURPHY ET AL: "Patented prostate cancer biomarkers", NATURE REVIEWS UROLOGY, vol. 9, no. 8, 3 July 2012 (2012-07-03), pages 464 - 472, XP055206631, ISSN: 1759-4812, DOI: 10.1038/nrurol.2012.130 *
Z. LI ET AL: "Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene", CARCINOGENESIS., vol. 27, no. 5, 1 May 2006 (2006-05-01), GB, pages 1054 - 1067, XP055365454, ISSN: 0143-3334, DOI: 10.1093/carcin/bgi324 *

Also Published As

Publication number Publication date
CA2863040A1 (en) 2013-08-08
SG10201605210PA (en) 2016-08-30
SG10201912312YA (en) 2020-02-27
SG11201404390WA (en) 2014-08-28
AU2013215448B2 (en) 2018-01-04
US20140303002A1 (en) 2014-10-09
IL262648A (en) 2018-12-31
JP6351112B2 (en) 2018-07-04
DK3179393T3 (en) 2020-07-27
JP2019013255A (en) 2019-01-31
US8725426B2 (en) 2014-05-13
AU2020202164B2 (en) 2022-02-10
AU2020202164A1 (en) 2020-04-16
MX2019007814A (en) 2019-09-05
CO7051010A2 (en) 2014-09-10
AU2013215448A1 (en) 2014-08-21
MX351626B (en) 2017-10-23
NZ722902A (en) 2017-12-22
MX2014009283A (en) 2014-09-11
IL254255A0 (en) 2017-10-31
HK1201881A1 (en) 2015-09-11
JP2015511814A (en) 2015-04-23
CA2863040C (en) 2022-04-19
EP3179393A2 (en) 2017-06-14
JP6908571B2 (en) 2021-07-28
AU2018201688B2 (en) 2020-02-27
EP3179393B1 (en) 2020-07-08
JP2017113008A (en) 2017-06-29
WO2013116144A1 (en) 2013-08-08
NZ627887A (en) 2016-08-26
IL262648B (en) 2020-07-30
EP2809812A1 (en) 2014-12-10
US11011252B1 (en) 2021-05-18
MX366164B (en) 2019-07-01
IL233709A (en) 2017-09-28
ES2812105T3 (en) 2021-03-16
EP3739595A2 (en) 2020-11-18
US20130196321A1 (en) 2013-08-01
IL254255B (en) 2018-11-29
AU2018201688A1 (en) 2018-04-05
EP3739595A3 (en) 2021-01-27
IL233709A0 (en) 2014-09-30
EP2809812A4 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
EP3739595A3 (en) Gene expression profile algorithm and test for determining prognosis of prostate cancer
EP4083233A3 (en) Method for using gene expression to determine prognosis of prostate cancer
WO2014140933A8 (en) Method for the prognosis and treatment of cancer metastasis
EP2908132A3 (en) Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
EP3236262A3 (en) Surrogate functional diagnostics test for cancer
NZ705645A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
EP4180531A3 (en) Nasal epithelium gene expression signature and classifier for the prediction of lung cancer
WO2008115419A3 (en) Gene expression markers for prediction of patient response to chemotherapy
MX2019013953A (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer.
IN2014DN08831A (en)
EP4282405A3 (en) Detection of cancer biomarkers using nanoparticles
WO2015100459A3 (en) Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
MX2014006404A (en) Methods and kits for the prognosis of colorectal cancer.
TR201907389T4 (en) Method for the prognosis and treatment of bone cancer with metastases caused by breast cancer.
WO2010118166A3 (en) Methods of predicting cancer risk using gene expression in premalignant tissue
EP3135774A3 (en) Complex sets of mirnas as non-invasive biomarkers for kidney cancer
EP2328105A3 (en) Method for determining the presence of disease
EP3425061A3 (en) Methods for predicting risk of metastasis in cutaneous melanoma
WO2012040500A3 (en) Direct blood assay for detection of circulating microrna in cancer patients
ES2662571T3 (en) Methods for evaluating endometrial receptivity of a patient after controlled ovarian hyperstimulation
WO2012069659A3 (en) Multimarker panel
WO2010093907A3 (en) An assay for the detection of recurrence in breast cancer using the novel tumor suppressor dear1
WO2012163941A3 (en) Marker for the detection and classification of leukemia from blood samples
MX2013013153A (en) Kiaa1456 expression predicts survival in patients with colon cancer.
WO2013190468A3 (en) Computer-based predictor for prostate cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 2809812

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20060101ALI20170809BHEP

Ipc: G06F 19/00 20110101AFI20170809BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1237068

Country of ref document: HK

17P Request for examination filed

Effective date: 20180306

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20191007

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602013070615

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: G06F0019000000

Ipc: C12Q0001680000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: G16B 25/10 20190101ALI20191218BHEP

Ipc: C12Q 1/68 20180101AFI20191218BHEP

INTG Intention to grant announced

Effective date: 20200122

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 2809812

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1288494

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200715

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20200723

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013070615

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER AND PEDRAZZINI AG, CH

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20200402688

Country of ref document: GR

Effective date: 20201116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201008

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201008

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201109

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201108

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2812105

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20210316

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013070615

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1288494

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200708

26N No opposition filed

Effective date: 20210409

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210128

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20230127

Year of fee payment: 11

Ref country code: FR

Payment date: 20230223

Year of fee payment: 11

Ref country code: DK

Payment date: 20230227

Year of fee payment: 11

Ref country code: CZ

Payment date: 20230201

Year of fee payment: 11

Ref country code: AT

Payment date: 20230201

Year of fee payment: 11

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602013070615

Country of ref document: DE

Owner name: MDX HEALTH SA, BE

Free format text: FORMER OWNER: GENOMIC HEALTH, INC., REDWOOD CITY, CALIF., US

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20130128

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230201

Year of fee payment: 11

Ref country code: IT

Payment date: 20230221

Year of fee payment: 11

Ref country code: GR

Payment date: 20230228

Year of fee payment: 11

Ref country code: BE

Payment date: 20230127

Year of fee payment: 11

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20230518 AND 20230524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230609

P02 Opt-out of the competence of the unified patent court (upc) changed

Effective date: 20230620

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: MDXHEALTH SA; BE

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: GENOMIC HEALTH, INC.

Effective date: 20230829

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240126

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240201

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240129

Year of fee payment: 12

Ref country code: GB

Payment date: 20240129

Year of fee payment: 12

Ref country code: CH

Payment date: 20240202

Year of fee payment: 12